The gene encoding the receptor tyrosine kinase ERBB2, also known as HER2, is amplified and/or overexpressed in up to 15% of breast cancers. These tumours are characterised by an aggressive phenotype and poor clinical outcome. Although therapies targeted at ERBB2 have proven effective, many patients fail to respond to treatment or become resistant and the reasons for this are still largely unknown. Using a high-throughput functional screen we assessed whether genes found to be recurrently amplified and overexpressed in ERBB2 þ ve breast cancers mediate resistance to the ERBB2-targeted agent lapatinib. Lapatinib-resistant ERBB2-amplified breast cancer cell lines were screened, in the presence or absence of lapatinib, with an RNA interference library targeting 369 genes recurrently amplified and overexpressed in both ERBB2-amplified breast cancer tumours and cell lines. Small interfering RNAs targeting a number of genes caused sensitivity to lapatinib in this context. The mechanisms of resistance conferred by the identified genes were further investigated and in the case of NIBP (TRAPPC9), lapatinib resistance was found to be mediated through NF-kB signalling. Our results indicate that specific amplified and/ or overexpressed genes found in ERBB2-amplified breast cancer may mediate response to ERBB2-targeting agents.
INTRODUCTION
Breast cancer is a heterogeneous disease characterised by a series of molecular subtypes, which have distinct molecular features and clinical behaviour.
1,2 Some of these molecular features, such as amplification and overexpression of genes, provide biomarkers and drug targets that can be utilised for treatment of the specific subgroup. 3 For example, expression of the oestrogen receptor in tumours is used to direct the use of anti-oestrogen agents such as tamoxifen and aromatase inhibitors, whereas tumour overexpression of ERBB2 or ERBB2 gene amplification are both a drug target as well as a prognostic and predictive biomarker for anti-HER2 agents. 4, 5 Although approximations of ERBB2 amplification and overexpression in breast cancer vary from study to study, conservative estimates suggest that somewhere between 15-20% of all breast cancers display this characteristic. [6] [7] [8] [9] [10] Overexpression of ERBB2 results in accumulation of ERBB2 receptors in the plasma membrane of the cell. ERBB2 interacts with itself and with other members of the EGFR family of growth factor receptors (EGFR, ERBB3 and ERBB4) to form homo-or heterodimers; these dimerisation events activate downstream molecular cascades that promotes cell proliferation, survival as well as tumour metastasis. [11] [12] [13] [14] [15] The current standard of care for early-stage and metastatic ERBB2 þ ve breast cancer is ERBB2-targeted treatment in the form of the monoclonal antibody trastuzumab in combination with chemotherapy. 4 In the case of metastatic ERBB2 þ ve breast cancer, a small-molecule inhibitor of ERBB2, lapatinib, has also been approved for treatment. 16 The mode of cell inhibition caused by these agents is not fully understood but in part involves downregulation of ERBB2 intracellular signalling cascades. [17] [18] [19] [20] The mechanism of action of trastuzumab has also been shown to involve both innate and adaptive immunity. 21, 22 Although both treatments have provided substantial benefits for patients, resistance to treatment remains a major problem. Only about half of the patients with ERBB2-overexpressing metastatic breast cancer respond when trastuzumab is given in addition to chemotherapy 4 and even less (32-34%) respond with trastuzumab monotherapy. 4, 23 In addition, many of the patients who initially respond to anti-ERBB2 therapy relapse within 1 year. 4, 16, 23 Several potential mechanisms of resistance to ERBB2-targeted treatments have been proposed, including activation of growth factor receptors, alterations of ERBB2 signalling molecules as well as the expression of drug-resistant ERBB2 isoforms. 24 From studies in trastuzumab-resistant breast cancer cell lines, elevated EGFR signalling has been implicated as a potential resistance mechanism to trastuzumab. 25 Similarly, heregulin-mediated activation of ERBB3 has also been shown to provide resistance to trastuzumab treatment in ERBB2-amplified cells. 26 Overexpression of the insulin-like growth factor 1 receptor has also been shown to provide resistance to ERBB2-targeted treatments, probably via activation of the ERBB2 insulin-like growth factor 1 receptor common mediators AKT and p42/p44. 27 Loss of PTEN function, found in up to 25% of ERBB2-positive breast cancers, 19 and activating mutations of PIK3CA, found in up to 30% of breast cancer, 28, 29 appear to mediate resistance to ERBB2-targeted treatment through their activation of the ERBB2 downstream PI3K/AKT/mTOR pathway. 19, 30, 31 A different mechanism of resistance has also been identified with the discovery of the truncated form of ERBB2 (p95ERBB2), which is generated by shedding of the extra cellular domain to which trastuzumab 1 The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK and binds. 32 This variant of ERBB2 retains its kinase activity and thus can still activate downstream signalling while being resistant to trastuzumab. 33 It should be noted, however, that although some studies suggested that expression of p95ERBB2 predicted resistance to trastuzumab treatment, 34, 35 others failed to find such an association and p95 appears to have no role in resistance to lapatinib.
36
ERBB2-amplified breast cancers have complex genomic profiles and harbour a number of discrete amplified genomic regions in addition to the ERBB2 amplicon. Of these, amplifications of regions on chromosomes 1q, 8q and 20q are the most common. [37] [38] [39] However, the biological significance of these additional amplification events is not yet clear, though they likely encompass oncogenes and potential therapeutic targets. 40, 41 Given the presence of co-amplifications in ERBB2-amplified breast cancers we hypothesised that these amplicons may contain genes whose overexpression results in resistance to anti-ERBB2-targeted therapy. To assess this hypothesis, we used a high-throughput lapatinib small interfering RNA (siRNA) sensitivity screen (HTS) using a siRNA library targeting recurrently amplified genes, which are overexpressed in ERBB2-amplified primary breast cancer tumours and cell lines. We demonstrate that genes mapping to recurrently amplified regions in ERBB2-amplified breast cancer provide resistance to ERBB2-targeted treatments.
RESULTS

Lapatinib sensitisation high-throughput siRNA Screen
To identify suitable breast cancer cell line models for our study we determined the ERBB2-amplification status and lapatinib sensitivity of 11 breast cancer cell lines (Figure 1a , Supplementary Figure 1 and described in Shiu et al. 42 Of the cell lines confirmed to be ERBB2-amplified by array-based comparative genome hybridisation and chromosome in situ hybridisation, three proved to be lapatinib sensitive, namely BT474, SKBR3 and ZR75.30, as previously described. 18 Seven cell lines, however, were defined as lapatinib resistant (SF 50 40.2 mM, Table 1 ). The lapatinibresistant ERBB2-amplified cell lines, HCC202, VP229, HCC1569, MDAMB453, HCC1954, JIMT1 and MDAMB361, where transfection conditions had been previously successfully optimised, 43 were taken forward for analysis with the HTS.
To enable the study of the significance of amplification events in ERBB2 þ ve breast cancer, a siRNA library had previously been constructed (as described in Shiu et al. 42 and Supplementary Table 1 ). The siRNA library used in our HTS-targeted genes (n ¼ 369) recurrently amplified and overexpressed in ERBB2-amplified breast cancer. These genes had previously been identified using array-based comparative genome hybridisation and microarray analysis of 45 ERBB2-amplified invasive breast cancers and 14 ERBB2-amplified breast cancer cell lines. The criteria for inclusion of a gene as a target in the library was that it was recurrently (n42) amplified and overexpressed in both tumours and cell lines. This criterion was set to triage the number of amplified and overexpressed genes down to a gene-set more likely to be of importance to the biology of ERBB2-amplified breast cancer and to increase the chance of having cell line models, which could be screened and perform functional analysis in.
The HTS involved reverse transfecting lapatinib-resistant cell lines with siRNA in a 96-well plate format after which cells were exposed to lapatinib for 5 days and the cell viability estimated (Figure 1b) . The screen was designed to detect modestly sensitising effects by using doses of lapatinib at or close to SF 80 . Quality control analysis of the screens indicated a high transfection efficiency in each cell line as demonstrated by the satisfactory dynamic range between the effect on cell viability of nontargeting siRNA when compared with siRNA targeting PLK1 (Supplementary Figure 2) . As an additional control, we assessed the effect on cell viability (in the absence of lapatinib) of siRNA targeting ERBB2. We found that the effect of ERBB2 siRNA on cell growth inhibition significantly correlated with the effect of cell growth by lapatinib (r 2 ¼ 0.79, Po0.001, Figure 1c ) suggesting that the siRNA transfection procedure used could deliver biologically relevant screening data.
Internal validation of lapatinib sensitisation effects identified by the screen was provided by the demonstration that siRNAs targeting RAC1 caused lapatinib sensitisation, and that siRNA targeting PTEN caused resistance to lapatinib as previously reported 30, 44 ( Figure 1d) . For each primary screen we identified the siRNAs with significant effects on lapatinib response, which targeted an amplified gene. Of the identified sensitising hits (Table 2) , 21 genes fulfilled these criteria. Full results of the screens are supplied as Supplementary Table 2 .
Validation of primary screen hits To exclude hits resulting from off-target effects the four individual siRNA oligonucleotides constituting each SMARTpool were investigated for their ability to reproduce the effect seen for the SMARTpool in the primary screen. A hit was defined as likely to be on-target if two or more of the four siRNAs targeting the same gene resulted in sensitisation to lapatinib. Although different siRNAs targeting the same gene had differing effects on the survival fraction in DMSO-treated cells (an effect possibly due to the different off-target profiles of different siRNAs), we were still able to validate the following genes as causing lapatinib sensitivity: RAB34, TP53INP1, RAC1, ATP6C1V1, C11ORF73, MLLT6, NIBP (TRAPPC9), NUFIP, PROCA1, RAB7L1, RAD21, SCRN2 and SPOP (Figure 2a) . Full results of the screens are found in Supplementary Table 3 and the survival effects of the siRNAs with or without lapatinib in Supplementary  Table 4 . Lapatinib dose-response survival analysis also confirmed the effects of a majority of the candidate sensitising genes, as seen by the shift of the lapatinib response curve to a less resistant profile (Figure 2b ). The sensitising effect of the siRNAs was considered validated if they caused at least a two-fold sensitisation to lapatinib when compared with control-transfected cells (Table 3) . We did, however, note that none of the siRNA sensitization effects caused a level of lapatinib sensitivity observed in inherently sensitive ERBB2 þ ve models; it is possible that the transient and incomplete nature of siRNA-induced gene silencing precludes seeing a total sensitization to the level in inherently sensitive models.
Cross-validation screen in ERBB2-amplified oesophageal cancer Approximately 20% of patients with oesophageal adenocarcinoma (EAC) have ERBB2 þ ve tumours. 45, 46 To assess whether our findings in ERBB2-amplified lapatinib-resistant breast cancer were relevant for ERBB2-amplified lapatinib-resistant EAC, we investigated the effect of silencing of our HTS hits in ERBB2-amplified EAC cell lines. The ERBB2 amplification status of EAC cell line models was determined by array-based comparative genome hybridisation. Three of the four cell lines analysed (OE33, the cisplatin-resistant OE33 clone (CROE33) and OE19) exhibited ERBB2 amplification (Supplementary Figure 3) . Of these cell lines only OE19 was lapatinib sensitive, CROE33 was intermediate sensitive and OE33 and the non-ERBB2-amplified FLO-1 cell line were resistant ( Figure 3a ). As expected, the lapatinib-sensitive cell line OE19 was also sensitive to ERBB2 gene silencing ( Figure 3b ). Validation siRNA screens were performed in the lapatinib-resistant cell lines OE33 and CR-OE33. In both cell lines silencing of TP53INP1 sensitised to lapatinib for three out of four siRNAs ( Figure 3c ). Full results of the validation screens can be found in Supplementary Table 3 . Moreover, TP53INP1 silencing sensitised to lapatinib over a wide range of concentrations in CROE33 and OE33 cells (Figure 3d ). Although TP53INP1 was not amplified in either OE33 or CROE33 both cell lines had the highest protein expression levels of TP53INP1 as compared with FLO and OE19 (Figure 3e ).
Functional analysis of validated hits
We originally hypothesised that amplicons in ERBB2 þ ve breast tumours may contain genes whose overexpression results in resistance to anti-ERBB2-targeted therapy. On this basis we selected two genes for further study, NIBP and TP53INP1, which were amplified and overexpressed in cell lines in which siRNA targeting caused a strong lapatinib sensitisation. Furthermore, the casual relationship between NIBP (aka TRAPPC9 trafficking protein particle complex 9) and NF-kB (nuclear factor kappa-light-chainenhancer of activated B cells) signalling, a known oncogenic process (see later) suggested the potential importance of this gene. To confirm the amplification status of these genes and to determine the degree of correlation with gene expression, we compared NIBP and TP53INP1 copy number status and mRNA expression in a cohort of 45 patients with ERBB2 þ ve tumours ( Figure 4a ). For both genes a significant association between amplification and overexpression was observed. The ERBB2-amplified cell line HCC1569, where TP53INP1 and NIBP where amplified and silencing sensitised to lapatinib, showed the highest TP53INP1 and high NIBP protein expression (Figures 4b and c) .
To identify signalling pathways/networks involved in the lapatinib resistance conferred by the NIBP and TP53INP1, functional protein association networks involving these proteins were investigated using STRING 9.0 (http://string-db.org/). Based on this analysis we identified HIPK2 and IKBKB as interacting partners of TP53INP1 and NIBP, respectively ( Figure 4d ). As these two genes represented potential druggable kinases, which could potentially be used in combination treatments with lapatinib we silenced them and assessed their ability to modulate lapatinib response. Silencing of IKBKB was shown to sensitise to lapatinib in HCC1569 where silencing of NIBP (TRAPPC9) sensitised to lapatinib, but not in the control cell lines JIMT1 and VP229 (Figure 4e) . No sensitisation to lapatinib was observed upon silencing of HIPK2. 
The The table shows the results of the lapatinib-sensitisation amplicon siRNA library screen and list of the 45 sensitising siRNA SMARTpools from the siRNA screen displayed with siRNA SMARTpool target gene name and drug effect Z-score for each cell line. Drug effect Z-scores in bold indicates scores below À 1.5.
RNAi Surviving fraction Surviving fraction Surviving fraction Surviving fraction Surviving fraction Surviving fraction Validated siRNA oligos were pooled and reverse transfected into the cell line they were a hit in. Twenty-four hours after plating and every 48 h after that, cells were treated with lapatinib ranging from 0-10 mM. Each treatment was done in triplicate. Cell viability was assessed after 7-10 days of lapatinib exposure using CellTiter-Glo Luminescent Cell viability assay. Error bars represent s.d.
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NIBP and the involvement of the NF-kB pathway in lapatinib resistance We hypothesised that the effect of NIBP depletion on lapatinib sensitivity could be explained by its ability to modulate NF-kB signalling. To study the role of NIBP and the NF-kB pathway in lapatinib resistance, we first generated NF-kB-mediated transcription reporter cell lines. The cell lines HCC1569 and HCC1954 were transduced with a lentivirus containing a NF-kB reporter construct where tandem repeats of the NF-kB transcriptional response element were regulating luciferase expression. After 2 weeks of puromycin selection, the cell lines were tested for the ability of the NF-kB reporter to respond to the NF-kB signalling activator tumour necrosis factor (TNFa). All reporter containing cell lines showed increased reporter activity upon TNFa treatment confirming the successful generation of the reporter cell lines (Figure 5a ). As the role of NIBP in NF-kB signalling has only been partially validated, 47 we tested the ability of NIBP silencing to reduce NF-kB reporter activity in the cell lines and compared these effects with the effect of silencing of the well-validated NF-kB signalling component RelA 48 ( Figure 5b ). For both cell lines, siRNA targeting RelA markedly decreased NF-kB reporter activity. NIBP silencing was also able to reduce NF-kB reporter activity. As no small molecule NIBP inhibitors exist that could be used in combination with lapatinib, we assessed the ability of a panel of inhibitors to other NF-kB pathway components to modify NF-kB reporter activity (Figure 5c ). The strongest effect on NF-kB reporter activity after 2 days of drug treatment of the NF-kB reporter cell lines HCC1569 and HCC1954 was seen for IMD-0354, a drug targeting IKBKB. To test if the IKBKB inhibitor IMD-0354 could sensitise to lapatinib, as IKBKB silencing was able to, we performed combination treatments of lapatinib and IMD-0354. For the lapatinib-resistant cell lines HCC1569 and HCC1954, a synergistic effect could be seen on both NF-kB reporter activity as well as cell inhibition (Figures 5d and e and Supplementary Figure 4) . Despite MDAMB453 cells being more sensitive to single agent IMD-0354, a clear but more modest effect on lapatinib sensitivity was also observed (Supplementary Figure4).
DISCUSSION
De novo and acquired resistance to ERBB2-targeted therapies remains a significant problem, which reduces the clinical benefit in patients. To address this issue, considerable efforts have been made to identify the molecular changes that could lead to resistance. Although genome-wide studies, together with the generation of cell lines resistant to ERBB2-targeting agents, have led to insights into the immediate signalling network in which ERBB2 acts and identified potential resistance-causing alterations, this has of yet not affected clinical practice. 31, 34, [49] [50] [51] Here, we show that by focusing on recurrently amplified and overexpressed genes, found in primary ERBB2 þ ve tumours and cell lines, we could identify genes that result in resistance to anti-ERRB2 agents without an obvious connection to previously described resistance mechanisms. Our confirmation of genes involved in ERBB2-targeting agent resistance such as PTEN and RAC1, using this approach, demonstrates the potential of this method. This is the first study to identify NIBP as being important for lapatinib response in a subgroup of ERBB2-amplified breast cancer models defined by NIBP amplification and/or overexpression. Importantly, NIBP amplification can be found in up to 11.1% of ERBB2 þ ve breast cancers and, in these patients, amplification correlates with NIBP mRNA overexpression (Po0.05). Thus far, NIBP has neither been implicated in cancer nor in therapeutic resistance. Instead, the best described roles of NIBP are in protein trafficking 52 and NF-kB signalling. 47 Although there is only one report describing this alternative role of NIBP, the data presented here support these previous observations. Hu et al 47 found that NIBP interacted with and activated the IKBKB kinase and activated NF-kB signalling. Although ERBB2 has long been known to be able to activate NF-kB signalling, 53 the mechanisms leading to this activation has yet to be fully elucidated. Merkhofer et al. 54 showed that ERBB2 activates NF-kB through the canonical NF-kB signalling protein IKKa and not via AKT/ PI3K. In addition, activation of RelA has been shown to be linked to the development of resistance in lapatinib-sensitive cell lines. 55 Taken together, these observations could suggest a synthetic gene interaction scenario where ERBB2 and NIBP activate NF-kB signalling via IKKa and IKBKB, respectively. Inhibition of either ERBB2 or NIBP on their own does not significantly affect viability but when simultaneously inhibited causes cell death.
In conclusion, we described how a focused functional genomics approach on genes recurrently amplified and overexpressed in ERBB2 breast cancer may be used to identify new mechanisms of resistance to ERBB2-targeted therapies. We demonstrated that by inhibiting NIBP, its interacting partner IKBKB or the NF-kB pathway using the IKBKB inhibitor IMD-0354, we sensitised resistant cells to normally sub-lethal doses of lapatinib. Targeting the NF-kB pathway in ERBB2 þ ve cancers dependent on this pathway for resistance could offer a therapeutic strategy for improving the response to treatment with ERBB2-targeting agents.
MATERIALS AND METHODS
Cell lines
Ten commercially available breast cancer cell lines known to harbour ERBB2 gene amplification and 1 non-ERBB2-amplified control were selected. They were purchased from their primary sources and were grown as per their exact recommendations. These included BT474, 
Drug sensitivity assays
Cells were seeded into 96-well plates. Twenty-four and 96 h after seeding, drugs were added with a final concentration ranging from 0-10 mM for lapatinib. After 5 days of drug exposure, cell viability was assessed with CellTiter-Glo Luminescent Cell Viability Assay (Promega, Madison, WI, USA) as per the manufacturer's instructions. To determine SF 50 values drug concentrations were logged, survival fractions calculated by dividing drug luminescence value with the luminescence value in DMSO wells and plotted against each other using GraphPAD Prism version 5.01 (GraphPad SMARTpool siRNA oligos against hit associated genes were reverse transfected into JIMT1, HCC1569 and VP229. Twenty-four hours after plating and every 48 h after that, cells were treated with lapatinib ranging from 0-10 mM. Each treatment was done in triplicate. Cell viability was assessed after 7-10 days of lapatinib exposure using CellTiter-Glo Luminescent Cell viability assay. Error bars represent s.d.
contained the individual siRNA species constituting the SMARTpool divided into one well each and was obtained in 2, 96-well plates from Dharmacon.
HTS screen method The ERBB2-amplified cell lines HCC1569 and HCC1954 transduced with an NF-kB reporter were plated in 96-well plates. Twenty-four and 96 h after plating cells were treated with 0 to 10 mM lapatinib and 0-1 mM IMD-0354. Each treatment was done in triplicate. NF-kB reporter activity was assessed 5 days after plating using the Dual-glo assay. Error bars represent s.d. (e) Identification of synergistic effects of lapatinib and the NF-kB inhibitor IMD-0354 on cell survival. The ERBB2-amplified cell lines HCC1569 and HCC1954 were plated in 96-well plates. 24 and 96 h after plating cells were treated with 0-10 mM lapatinib and 0-1 mM IMD-0354. Each treatment was done in triplicate. NF-kB reporter activity was assessed 5 days after plating using the CellTiter-Glo Luminescent assay. Error bars represent s.d.
manufacturers' instructions in a 96-well format. Master transfection plates were divided into 6 replica plates whereupon cells were added. Forty-eight hours after transfection, replica plates were either treated or not treated with lapatinib (0.4 mM for HCC202 and VP229, 1 mM for HCC1569, HCC1954, JIMT1, MDAMB361 and MDAMB453). Media in replica plates where replenished every 48 h and cell viability was assessed after 5 days of drug exposure using CellTiter-Glo Luminescent Cell Viability Assay (Promega) as per manufacturer's instructions to determine the drug effect of individual SMARTpool siRNAs (that is, genes that when silenced only had an effect on viability with lapatinib treatment), we first normalised cell viability data from each well to the median of all effects in that plate for no treatment (DMSO) and lapatinib treatment, respectively. The drug effect value was generated by subtracting the centred lapatinib value from the centred DMSO value for each SMARTpool. For each SMARTpool the Z score/median absolute deviation method was used to identify hits. For the Z-score the s.d. of the screen was estimated from the median absolute deviation of all 400 SMARTpools adjusted by a factor of 1.4826 for equivalence with an asymptotically normal distribution.
Validation of HTS screen
Four distinct siRNA species targeting each gene were used to validate hits from the high-throughput screen. For each siRNA, survival fractions compared with siCTRL were calculated. Next, DMSO siRNA survival fractions were compared with corresponding lapatinib siRNA survival fractions. siRNAs with survival fraction differences 40.15, where survival fraction of siRNA with DMSO was over 0.8 and where survival fraction of siRNA with lapatinib was under 0.8 were considered validated.
Western blotting
Cell lysates were separated using 4-12% SDS-PAGE Bis-Tris gel, transferred to nitrocellulose membrane, blocked in 5% milk and blotted with antibodies. Immunoblotting was performed according to the manufacturer's instructions using enhanced chemiluminescence. Antibodies targeting the following epitopes were used: NIBP (Abcam, Cambridge, UK), and TP53INP1 (GTX112066S; Source Bioscience, Nottingham, UK). b-tubulin (T4026; Sigma, St Louis, MO, USA).
Statistical analysis
Statistical analysis was performed with SPSS package version 15 (Chicago, IL, USA) or GraphPad Prism version 5.01 (GraphPad Software).
